The MLR Review Tax Nobody Benchmarks

MLR review exists for good reason, and nobody serious argues it shouldn't. But the extra rounds it adds and the workflow built around it rarely get priced or benchmarked the way any other seven-figure marketing cost would be.

Ask a pharma or consumer health marketing team what actually slows a campaign down and they will not say creative. They will say MLR. Every piece of content, an ad, a label claim, a physician-facing leave-behind, a product page, a social post, has to clear medical, legal, and regulatory review before it goes anywhere. That process exists for a good reason: getting a health claim wrong carries real consequences, for patients and for the company. Nobody serious argues MLR review should not exist.

What gets far less scrutiny is what the process actually costs, and whether it runs at the standard a well-managed marketing operation should hold itself to.

The cost that never gets priced

Agency scopes get written for the work: strategy, creative development, production. They rarely get written for the number of review rounds a piece of content will actually need to clear MLR. So when legal flags a claim in round two, or a regulatory reviewer asks for a substantiation reference in round three, the agency either absorbs the cost quietly or bills it as a change order. Either way, nobody is tracking whether four rounds of revision is normal for that kind of asset or a sign the brief was wrong from the start.

That gap compounds. A marketing team running a full content calendar across multiple products and multiple markets is absorbing review cycles as a fixed cost of doing business, without ever asking whether the number of rounds, the average turnaround per round, or the rate of late-stage claim changes is actually competitive with how other companies run the same process. Most pharma and consumer health marketing organizations have never benchmarked their MLR cycle time or their agency's rework rate against anything. It just is what it is, until someone finally asks.

Consumer health is not exempt

It is worth being precise about who this applies to. A prescription pharma brand runs true clinical medical review, tied to approved labeling and adverse event language, and that is a different discipline with a different bar. Consumer healthcare is not doing that. But a consumer health brand marketing an OTC product, a supplement, or a personal care claim is still gated by legal and regulatory review before anything ships, because FTC substantiation standards and FDA labeling rules do not disappear just because there is no prescription attached. The review is lighter. It is not absent.

We have worked inside a consumer healthcare business, Arcadia Consumer Healthcare, and the pattern holds even at that lighter weight: content moves through more approval steps than the marketing team originally scoped for, and almost nobody goes back to ask whether the workflow itself, not just the claims being reviewed, is built for how the business actually operates today.

Where the friction actually lives

The MLR bottleneck almost never turns out to be one slow reviewer sitting on approvals. It is usually structural. Nobody owns the queue, so content sits between departments with no clear turnaround expectation on either side. Version control lives across email threads and shared drives instead of one system of record, so reviewers are sometimes commenting on a draft that has already been superseded. And most organizations bought a review management platform, something like Veeva Vault PromoMats is the category standard, years ago and never redesigned the workflow around it, so the tool logs approvals without actually shortening the path to one.

That last point is where MLR compliance and marketing procurement start to overlap. The review platform is one license among several a commercial team is paying for. The agency retainer is priced without an honest number attached to review cycles. Neither one gets audited with the rigor a company would apply to a manufacturing or supply contract of equivalent size, and both are large enough line items to deserve it.

Where to start

Two questions are enough to find out whether this is costing more than it should. Does anyone in the organization know, with an actual number, how many review rounds the average piece of content takes to clear MLR, and how that compares to a year ago? And is the agency scope written to account for review cycles as a real cost driver, or is rework being absorbed quietly by whichever side has less leverage in that relationship?

If the honest answer to either one is we don't track that, the process is probably costing more than anyone in the room would guess, and right now nobody has the number to prove it either way.